Summary & Overview
CPT 81188: CSTB Gene Expansion Analysis
CPT code 81188 represents a laboratory technical procedure that characterizes sequence changes in the cystatin B gene (CSTB), most often used to detect expanded alleles. This molecular genetic test is clinically relevant for diagnosing or confirming conditions associated with CSTB expansions. Nationally, accurate coding for such specialized genetic tests supports appropriate laboratory reimbursement, claims processing, and aggregation of utilization data for rare genetic disorders.
Key payers covered in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of the code’s clinical purpose and service setting, and a summary of common modifiers observed with genetic laboratory services. The publication outlines benchmarking considerations and common billing practices for molecular genetic testing to help coding professionals and health policy stakeholders understand where CPT code 81188 fits within laboratory service lines.
This report also provides clinical context for the test, typical sites of service, and notes where input data were not available. The content is presented to inform payers, laboratory billing teams, and policy analysts on coding classification and operational implications for specialized genetic testing.
Billing Code Overview
CPT code 81188 describes a laboratory technical service that characterizes changes in the cystatin B gene (CSTB), typically to detect abnormal alleles involving expanded sequences. This service involves laboratory analysis of patient DNA to determine the presence and extent of sequence expansions in the CSTB gene.
-
Service type: Molecular genetic testing / laboratory technical component
-
Typical site of service: Clinical molecular diagnostics laboratory or reference genetic testing laboratory
Data not available in the input.
Clinical & Coding Specifications
Clinical Context
A patient presents to a neurology clinic with progressive myoclonic seizures, action myoclonus, and gait instability suspicious for Unverricht–Lundborg disease or other progressive myoclonic epilepsy. The neurologist orders molecular testing of the cystatin B gene to detect pathogenic expanded repeat alleles. Blood is drawn in the outpatient phlebotomy lab; the specimen is sent to a molecular diagnostics laboratory where a lab analyst performs the technical testing using PCR and/or repeat-primed assays to characterize CSTB repeat expansions. Results are interpreted by a laboratory director or molecular pathologist and reported to the ordering neurologist. Typical sites of service include outpatient hospital laboratories, independent clinical laboratories, and hospital inpatient laboratories when testing is ordered during admission. The typical patient is an adolescent or young adult with progressive myoclonic epilepsy features or a family history of CSTB-related disease undergoing diagnostic confirmation, genetic counseling, or pre-symptomatic testing.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
26 | Professional component | When billing only the professional interpretation component separate from the technical lab testing |
TC |